INCB052793

PreclinicalSmall molecule

Incyte

INCB052793 is one of 58 small molecule programs targeting Myelofibrosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyelofibrosisActive, not recruiting

MyelofibrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

139 competitors in Myelofibrosis

#DrugCompanyPhaseTrials

Ojjaara

GGlaxo Dba Glaxosmithkline

Phase 3

6 2

Vonjo

OOrsoBio, Inc

Phase 3

4 3

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

3 4

Rytelo

GGeron Corporation

Phase 3

3 5

Best Available Therapy

Novartis

Phase 3

6 6

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 7

Navitoclax

AbbVie

Phase 3

5 8

Cellcept

Roche

Phase 2

5 9

Fludara

Sanofi

Phase 2

5 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelofibrosis1 trial

Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

No longer available· Incyte logo

Incyte··NCT03906344

Advanced Malignancies1 trial

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02265510·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for INCB052793. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCB052793 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCB052793. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Incyte

INCB052793

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelofibrosis1 trial

Advanced Malignancies1 trial

References

Drug Info

Quick Facts

Related News